A LIGHTFUL nanomedicine overcomes EGFR-mediated drug resistance for enhanced tyrosine-kinase-inhibitor-based hepatocellular carcinoma therapy.

Yi K, Kong H, Zheng C, Zhuo C, Jin Y, Zhong Q, Mintz RL, Ju E, Wang H, Lv S, Lao YH, Tao Y, Li M
Biomaterials. 2023 Nov;302:122349. doi: 10.1016/j.biomaterials.2023.122349. Epub 2023 Oct 6. PubMed Article

Plasmids from Article

No plasmids are currently publicly available from Addgene for this article.